AVHHL (AVITA Medical) Accounts Receivable : $11.79 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is AVITA Medical Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. AVITA Medical's accounts receivables for the quarter that ended in Dec. 2024 was $11.79 Mil.

Accounts receivable can be measured by Days Sales Outstanding. AVITA Medical's Days Sales Outstanding for the quarter that ended in Dec. 2024 was 58.43.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. AVITA Medical's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was $-0.20.

AVITA Medical Accounts Receivable Historical Data

The historical data trend for AVITA Medical's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVITA Medical Accounts Receivable Chart

AVITA Medical Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Dec22

Dec23

Dec24

Accounts Receivable

Get a 7-Day Free Trial

2.08

3.47

3.52

7.66

11.79

AVITA Medical Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Accounts Receivable	Get a 7-Day Free Trial															7.66	7.08	8.72	10.29	11.79

AVITA Medical Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

AVITA Medical Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

AVITA Medical's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	11.786	/	18.406	*	91
=	58.43

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), AVITA Medical's accounts receivable are only considered to be worth 75% of book value:

AVITA Medical's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(35.885	+	0.75 * 11.786	+	0.5 * 7.269	-	75.212
-	0	-	0)	/	131.770
=	-0.20

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

AVITA Medical Accounts Receivable Related Terms

Thank you for viewing the detailed overview of AVITA Medical's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

AVITA Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AVITA Medical Inc (OTCPK:AVHHL) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

RCEL:USA 51KA:Germany 51KA:Germany 51KB:Germany AVH:Australia

Address

28159 Avenue Stanford, Suite 220, Valencia, Santa Clarita, CA, USA, 91355

Website

https://www.avitamedical.com

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.